Need a direct line?
Feel free to contact us for more information about our offers.
+33(0)1 69 86 58 60
contact@ipvf.fr
[et_pb_section fb_built= »1″ _builder_version= »4.2.2″][et_pb_row _builder_version= »4.2.2″][et_pb_column type= »4_4″ _builder_version= »4.2.2″][et_pb_text _builder_version= »4.2.2″ header_text_color= »#0c71c3″]
[/et_pb_text][/et_pb_column][/et_pb_row][et_pb_row _builder_version= »4.2.2″ width= »100% » max_width= »2560px » module_alignment= »center »][et_pb_column type= »4_4″ _builder_version= »4.2.2″][et_pb_text _builder_version= »4.2.2″ header_3_text_color= »#0c71c3″ custom_margin= »15px|||100px|false|false »]
Blindness can result from the loss of either photoreceptors in age-related macular degeneration or retinal ganglion cells in glaucoma. Following photoreceptor degeneration, electrical activation of residual retinal neurons can restore some visual function in blind patients. However, the perception provided by current retinal prostheses does not allow face recognition or autonomous motion in an unknown environment. To reach this level of perception, we have assessed a new photovoltaic retinal implant and optogenetic therapy. The talk will present these technologies to discuss potential developments.
[/et_pb_text][/et_pb_column][/et_pb_row][et_pb_row _builder_version= »4.2.2″][et_pb_column type= »4_4″ _builder_version= »4.2.2″][et_pb_text _builder_version= »4.2.2″]
by Serge Picaud, Institut de la Vision, INSERM
[/et_pb_text][/et_pb_column][/et_pb_row][/et_pb_section]
Feel free to contact us for more information about our offers.
+33(0)1 69 86 58 60contact@ipvf.fr[et_pb_section fb_built= »1″ _builder_version= »4.2.2″][et_pb_row _builder_version= »4.2.2″][et_pb_column type= »4_4″ _builder_version= »4.2.2″][et_pb_text _builder_version= »4.2.2″ header_text_color= »#0c71c3″]
[/et_pb_text][/et_pb_column][/et_pb_row][et_pb_row _builder_version= »4.2.2″ width= »100% » max_width= »2560px » module_alignment= »center »][et_pb_column type= »4_4″ _builder_version= »4.2.2″][et_pb_text _builder_version= »4.2.2″ header_3_text_color= »#0c71c3″ custom_margin= »15px|||100px|false|false »]
Blindness can result from the loss of either photoreceptors in age-related macular degeneration or retinal ganglion cells in glaucoma. Following photoreceptor degeneration, electrical activation of residual retinal neurons can restore some visual function in blind patients. However, the perception provided by current retinal prostheses does not allow face recognition or autonomous motion in an unknown environment. To reach this level of perception, we have assessed a new photovoltaic retinal implant and optogenetic therapy. The talk will present these technologies to discuss potential developments.
[/et_pb_text][/et_pb_column][/et_pb_row][et_pb_row _builder_version= »4.2.2″][et_pb_column type= »4_4″ _builder_version= »4.2.2″][et_pb_text _builder_version= »4.2.2″]
by Serge Picaud, Institut de la Vision, INSERM
[/et_pb_text][/et_pb_column][/et_pb_row][/et_pb_section]
Feel free to contact us for more information about our offers.
+33(0)1 69 86 58 60contact@ipvf.fr
